The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment Camizestrant improved patient survival without the disease getting ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...

AstraZeneca's new therapy, camizestrant, shows promising results in improving survival rates for patients with advanced ...

A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...